amgen weight loss news

Amgen's Weight Loss Result Is a Win for Eli Lilly

Amgen Drug Delivers More Weight Loss Than Competitors

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

MarketWatch on MSN · 13h

Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year,

The Motley Fool on MSN · 16h

Why Amgen's Weight Loss Result Is a Win for Eli Lilly

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.

23h

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

11h

Amgen’s Stock Outlook: Balancing Maritide’s Weight Loss Data Concerns and Diabetes Treatment Potential

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results